Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer
25 mai 2021 08h00 HE
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines to Present at Upcoming Investor Conferences
14 mai 2021 09h00 HE
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines Prices Public Offering of Common Stock
13 mai 2021 22h39 HE
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines Announces Proposed Public Offering of Common Stock
11 mai 2021 16h22 HE
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results
11 mai 2021 08h00 HE
|
Praxis Precision Medicines, Inc.
Expands pipeline with new indications for PRAX-114 and PRAX-944 PRAX-114 Phase 2 trial for treatment of post-traumatic stress disorder to initiate in 2H21 PRAX-114 Phase 2 trial for...
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
30 avr. 2021 09h00 HE
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Cudkowicz, M.D.
29 avr. 2021 08h00 HE
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D.
15 avr. 2021 16h05 HE
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE
14 avr. 2021 09h00 HE
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines to Present at Stifel’s 3rd Annual CNS Day
24 mars 2021 08h00 HE
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...